Pharvaris (NASDAQ:PHVS) Rating Reiterated by Wedbush

Pharvaris (NASDAQ:PHVS)‘s stock had its “outperform” rating reissued by stock analysts at Wedbush in a research note issued to investors on Thursday, Benzinga reports. They presently have a $35.00 price target on the stock. Wedbush’s price objective suggests a potential upside of 59.82% from the company’s previous close.

Separately, JMP Securities reaffirmed a “market outperform” rating and set a $49.00 target price on shares of Pharvaris in a report on Wednesday, February 14th.

Pharvaris Stock Down 1.8 %

NASDAQ:PHVS opened at $21.90 on Thursday. The business’s 50-day moving average price is $25.01 and its 200 day moving average price is $23.27. Pharvaris has a 52-week low of $7.93 and a 52-week high of $33.00.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of PHVS. Goldman Sachs Group Inc. purchased a new position in Pharvaris in the 4th quarter worth about $240,000. Price T Rowe Associates Inc. MD purchased a new position in Pharvaris in the 4th quarter worth about $23,638,000. Sphera Funds Management LTD. purchased a new position in Pharvaris in the 4th quarter worth about $6,872,000. Viking Global Investors LP increased its stake in Pharvaris by 13.2% in the 4th quarter. Viking Global Investors LP now owns 3,656,923 shares of the company’s stock worth $102,577,000 after purchasing an additional 425,000 shares in the last quarter. Finally, Novo Holdings A S increased its stake in Pharvaris by 15.8% in the 4th quarter. Novo Holdings A S now owns 1,539,325 shares of the company’s stock worth $43,178,000 after purchasing an additional 210,000 shares in the last quarter.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).